scholarly journals HCV-Induced Oxidative Stress: Battlefield-Winning Strategy

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Khadija Rebbani ◽  
Kyoko Tsukiyama-Kohara
Keyword(s):  
Oxidative Stress ◽  
Immune Response ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Infection ◽  
Liver Diseases ◽  
Winning Strategy ◽  
Critical Role ◽  
Markers Of Oxidative Stress ◽  
Induce Hepatocarcinogenesis

About 150 million people worldwide are chronically infected with hepatitis C virus (HCV). The persistence of the infection is controlled by several mechanisms including the induction of oxidative stress. HCV relies on this strategy to redirect lipid metabolism machinery and escape immune response. The 3β-hydroxysterol Δ24-reductase (DHCR24) is one of the newly discovered host markers of oxidative stress. This protein, as HCV-induced oxidative stress responsive protein, may play a critical role in the pathogenesis of HCV chronic infection and associated liver diseases, when aberrantly expressed. The sustained expression of DHCR24 in response to HCV-induced oxidative stress results in suppression of nuclear p53 activity by blocking its acetylation and increasing its interaction with MDM2 in the cytoplasm leading to its degradation, which may induce hepatocarcinogenesis.

Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study

2021 ◽  
Author(s):  
Haidi Karam-Allah Ramadan ◽  
Gamal Badr ◽  
Nancy K Ramadan ◽  
Aml Sayed
Keyword(s):  
Immune Response ◽  
Liver Cirrhosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Immune Responses ◽  
Signaling Pathways ◽  
Liver Diseases ◽  
Stat Signaling ◽  
Chronic Hcv ◽  
Direct Acting

Abstract The use of direct-acting antivirals (DAAs) therapy for the treatment of hepatitis C virus (HCV) results in a high sustained virological response (SVR) and subsequently alters liver immunologic environment. However, hepatocellular carcinoma (HCC) may occur after DAAs treatment. We aimed to clarify changes of immune responses, PI3K/AKT and JAK/STAT signaling pathways in HCV-induced liver diseases and HCC following DAAs treatment. Four cohorts are classified as chronic HCV patients, HCV-related cirrhosis without HCC, HCV-related cirrhosis and HCC, and healthy control group. The patient groups were further divided into treated or untreated with DAAs with SVR12. Increased percentages of CD3, CD8 and CD4, decreased CD4/FoxP3/CD25, CD8/PD-1 and CD19/PDL-1 were found in DAAs-treated patients in the three HCV groups. Following DAAs therapy, the levels of ROS, IL-1β, IL-6, IL-8 and TNF-α were significantly decreased in the three HCV groups. Treated HCV patients showed up regulation of p-AKT and p-STAT5 and down regulation of p-STAT3, HIF-1α and COX-2. In conclusion, DAAs enhance the immune response in chronic HCV and liver cirrhosis, hence our study is the first to show change in PI3K/AKT and JAK/STAT signaling pathways in different HCV-induced liver diseases after DAAs. In chronic HCV, DAAs have better impact on the immune response while in liver cirrhosis not all immune changes were prominent.

scholarly journals Hepatitis C Virus Reveals a Novel Early Control in Acute Immune Response

2011 ◽  
Vol 7 (10) ◽  
pp. e1002289 ◽  
Author(s):  
Noëlla Arnaud ◽  
Stéphanie Dabo ◽  
Daisuke Akazawa ◽  
Masayoshi Fukasawa ◽  
Fumiko Shinkai-Ouchi ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis C Virus ◽  
Hepatitis C

scholarly journals Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments

Hepatology ◽  
1998 ◽  
Vol 28 (3) ◽  
pp. 810-814 ◽  
Author(s):  
Roberto Burioni ◽  
Paola Plaisant ◽  
Aldo Manzin ◽  
Domenico Rosa ◽  
Valeria Delli Carri ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Humoral Immune Response ◽  
Humoral Immune ◽  
Fab Fragments ◽  
E2 Glycoprotein
Sign in / Sign up

Export Citation Format

Share Document